Compassionate Access trial of MDMA-assisted therapy in Canada
Latest Information Update: 20 Mar 2024
At a glance
- Drugs Methylenedioxymetamfetamine (Primary)
- Indications Post-traumatic stress disorders
- Focus Expanded access; Therapeutic Use
- 12 Jul 2021 According to a Numinus Wellness Inc media release, this trial builds on strong MAPS Phase 3 results.
- 12 Jul 2021 According to a Numinus Wellness Inc media release, study preparations are now transitioning into the final stages of training staff, importing medication and obtaining ethical approval to allow the recruitment of participants according to COVID-19 public health protocols. During the study, research, medical and therapist staff at Numinus will collect data on the safety and effectiveness of MDMA-assisted therapy to inform Health Canada and support making MDMA-assisted therapy available to individ
- 12 Jul 2021 According to a Numinus Wellness Inc media release,this study is being pursued in collaboration with MAPS Public Benefit Corporation (MAPS PBC), a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), the leading developer of MDMA-assisted therapy training programs, treatment protocols and research.